One year of setmelanotide provided reductions in BMI z score for children and body weight for adults with Bardet-Biedl syndrome, according to data published in Obesity.
As Healio previously reported, the FDA approved setmelanotide (Imcivree, Rhythm Pharmaceuticals) for children and adults aged at least 6 years with Bardet-Biedl syndrome in 2022. In an indirect comparison study, researchers examined weight outcomes among participants in a phase 3 trial receiving setmelanotide with people in the Clinical Registry Investigating Bardet-Biedl Syndrome (CRIBBS) database who did not use the drug. At

For a fulfilling career in ophthalmology, find the right cultural fit during every step of the journey, from training to residency and beyond.
“If you don’t fit the institution’s culture, you are destined for unhappiness,” Jane C. Edmond, MD, of the University of Texas at Austin, told Healio in this episode of Steeped Insights, a video blog series produced by Women in Ophthalmology and Healio. “Residents who match into a program with a poor cultural fit will be miserable, and so will their attendings and staff.”
{{VIDEO}}
Over a cup of tea, host Karen Chen, MD, of The Permanente Medical Group,

NEW ORLEANS — Results presented here showed GLP-1 receptor agonists may be associated with lower ED utilization and a reduction in surgical site infections and revisions for a range of orthopedic procedures.
“GLP-1 use is becoming far more prevalent. It is going to require incorporation into our preoperative medication review, risk stratification and perioperative planning,” Haroun Haque, MS, a third-year medical student at SUNY Downstate Medical Center, said in his presentation at the American Academy of Orthopaedic Surgeons Annual Meeting. “Of course, we need more prospective studies to

Patients with a history of breast, kidney, lung and several other types of cancer who undergo solid organ transplant have a significantly higher risk for developing a second malignancy at the same site after transplant.
An evaluation of more than 90% of solid organ transplant recipients in the United States also showed associations between different malignancies, including a significantly higher risk for lung and prostate cancer among patients with liver cancer before transplant.
“Cancer is a major problem after organ transplantation for a number of reasons,” Eric A. Engels, MD, MPH, director

Treatment with biologic or targeted synthetic disease-modifying antirheumatic drugs failed to mitigate bone mineral density loss in rheumatoid arthritis, according to data published in Arthritis & Rheumatology.
“Because inflammation is considered one of the multiple causes of systemic osteoporosis in RA, it has been hypothesized that suppressing inflammation with [biologic/targeted synthetic (b/ts)] DMARDs may also benefit systemic bone loss,” Takafumi Aritomi, MD, of the Hospital of the University of Occupational and Environmental Health, in Kitakyushu, Japan, and colleagues